Article | 2020.10.14
Of all the vaccines developed at the Institut Pasteur for SARS-CoV-2 (the virus that causes COVID-19), the DNA vaccine undoubtedly involves the most novel approach, since no vaccine using this technology has yet been commercialized* (for humans).
Fiche maladie | 2020.01.21
The SARS-CoV-2 coronavirus, discovered in December 2019 in the province of Wuhan in China, is responsible for COVID-19. This highly contagious emerging infectious disease spreads by airborne transmission and surface contamination. Although COVID-19 can be asymptomatic, it can also cause a variety of symptoms, including severe respiratory distress that may prove fatal. Vaccination and basic health...
Article | 2020.03.16
On January 9, 2020, Chinese health authorities and the World Health Organization (WHO) officially announced the discovery of a novel coronavirus (first named 2019-nCoV, then officially SARS-CoV-2). This new virus is the pathogen responsible for the infectious respiratory disease called COVID-19 (CoronaVIrus Disease). Following the announcement of the first cases and the declaration of...
Document de presse | 2023.03.28
More than three years after the start of the COVID-19 epidemic, mathematical modeling is still providing us with valuable insights, as shown in a recent study on household transmission of SARS-CoV-2 by the Hong Kong University School of Public Health and the Institut Pasteur/Université Paris Cité. Scientists believe that there is a subset of individuals with SARS-CoV-2 who are three times more...
News | 2020.10.07
Institut Pasteur's expertise in infectious diseases has made it one of the major players in research against Covid-19. For the 2020 Pasteurdon (the Institut Pasteur’s public fundraising campaign), a podcast in French has been recorded. Two Pasteurian researchers, Sylvie van der Werf and Arnaud Fontanet, talk about this pandemic and the Institut Pasteur's actions to fight the virus. They also...
Article | 2020.03.27
VACCINE CANDIDATES1. Development of an animal model and accelerated development of a DNA vaccine candidate(SCARD SARS-CoV-2 project)Aims:To develop a mouse model of SARS-CoV-2 infection.This will not only enable us to evaluate the efficacy of the vaccine; it will also facilitate in vivo research on SARS-CoV-2. To evaluate the immunogenicity (ability to induce a specific immune reaction) and...
News | 2023.04.17
The link between the viral variant and length of the COVID-19 incubation period is still a matter of debate. Scientists from the Institut Pasteur conducted a survey of thousands of volunteers for more than a year to provide an answer.
News | 2023.02.20
Scientists at the Institut Pasteur have successfully synthesized two novel molecules that are active against several variants of the virus responsible for COVID-19. The discovery could inspire new families of antiviral drugs against future emerging viral diseases.
Page avancée | 2022.01.12
The Institut Pasteur’s list of scientific publications on SARS-CoV-2 coronavirus and Covid-19 disease.
News | 2020.02.26
During the weekend of February 22-23, 2020, the epidemic situation evolved worldwide with the intensification of outbreaks in South Korea, Japan and Singapore, and the appearance of new outbreaks in Iran and Italy. In these countries, we are witnessing a community transmission with no identified link with cases imported from China. This situation raises many questions. How is the disease...